149 related articles for article (PubMed ID: 33573404)
1. Systematic review and meta-analysis of HPV vaccination in women with systemic lupus erythematosus (SLE).
Infante V; Miyaji KT; Soarez PC; Sartori AMC
Expert Rev Vaccines; 2021 Mar; 20(3):309-318. PubMed ID: 33573404
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.
Mok CC; Ho LY; Fong LS; To CH
Ann Rheum Dis; 2013 May; 72(5):659-64. PubMed ID: 22589375
[TBL] [Abstract][Full Text] [Related]
3. Systemic lupus erythematosus following HPV immunization or infection?
Soldevilla HF; Briones SF; Navarra SV
Lupus; 2012 Feb; 21(2):158-61. PubMed ID: 22235047
[TBL] [Abstract][Full Text] [Related]
4. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
Vaccine; 2017 May; 35(20):2642-2646. PubMed ID: 28404357
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of human papillomavirus vaccine coadministered with other vaccines in individuals aged 9-25 years: A systematic review and meta-analysis.
Li Y; Zhu P; Wu M; Zhang Y; Li L
Vaccine; 2020 Jan; 38(2):119-134. PubMed ID: 31831220
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis.
Pugès M; Biscay P; Barnetche T; Truchetet MÉ; Richez C; Seneschal J; Gensous N; Lazaro E; Duffau P
Rheumatology (Oxford); 2016 Sep; 55(9):1664-72. PubMed ID: 27160278
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis.
Liao Z; Tang H; Xu X; Liang Y; Xiong Y; Ni J
PLoS One; 2016; 11(2):e0147856. PubMed ID: 26845680
[TBL] [Abstract][Full Text] [Related]
9. Lupus and vaccinations.
Mathian A; Pha M; Amoura Z
Curr Opin Rheumatol; 2018 Sep; 30(5):465-470. PubMed ID: 29889693
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis.
Setiawan D; Luttjeboer J; Pouwels KB; Wilschut JC; Postma MJ
Jpn J Clin Oncol; 2017 Mar; 47(3):265-276. PubMed ID: 28042137
[TBL] [Abstract][Full Text] [Related]
12. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
[TBL] [Abstract][Full Text] [Related]
13. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis.
Adawi M; Bragazzi NL; McGonagle D; Watad S; Mahroum N; Damiani G; Conic R; Bridgewood C; Mahagna H; Giacomelli L; Eggenhöffner R; Mahamid M; Pigatto PDM; Amital H; Watad A
Autoimmun Rev; 2019 Jan; 18(1):73-92. PubMed ID: 30408581
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
Joura EA; Ulied A; Vandermeulen C; Rua Figueroa M; Seppä I; Hernandez Aguado JJ; Ahonen A; Reich O; Virta M; Perino A; Peris Tuser M; Peters K; Origoni M; Raspagliesi F; Tjalma WAA; Tummers P; Woelber L; Nieminen P; van Damme P; Sehouli J; Fiol Ruiz G; Brucker S; Fehm T; Cheon K; Rawat S; Luxembourg A; Wittke F
Vaccine; 2021 May; 39(20):2800-2809. PubMed ID: 33676783
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
17. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
[TBL] [Abstract][Full Text] [Related]
18. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus.
Mok CC; Ho LY; To CH
Vaccine; 2018 May; 36(23):3301-3307. PubMed ID: 29699792
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
Rotstein Grein IH; Pinto NF; Lobo A; Groot N; Sztajnbok F; da Silva CAA; Paim Marques LB; Appenzeller S; Islabão AG; Magalhães CS; de Almeida RG; Bica B; Fraga M; da Fraga ACM; Dos Santos MC; Robazzi T; Terreri MTR; Bandeira M; Pasmans H; Schepp R; van der Klis F; de Roock S; Wulffraat N; Pileggi G
Lupus; 2020 Jul; 29(8):934-942. PubMed ID: 32501172
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis.
García-Carrasco M; Mendoza-Pinto C; Rojas-Villarraga A; Molano-González N; Vallejo-Ruiz V; Munguía-Realpozo P; Colombo AL; Cervera R
Autoimmun Rev; 2019 Feb; 18(2):184-191. PubMed ID: 30572140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
